Physician profile
Michael W Morse
NPI 1235187386
$149,304.69
in general payments reported to CMS, 2019-2025
40 companies · $3,024 in 2025
The $3,024 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $34K · 2021: $67K · 2022: $12K · 2023: $13K · 2024: $8,165 · 2025: $3,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,228 · Travel and Lodging: $1,997 · Consulting Fee: $150 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,237.50 |
| Food and Beverage | $6,228.18 |
| Travel and Lodging | $1,997.14 |
| Consulting Fee | $150.00 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $73,755.98 | 2019-2022 | |
| Abbvie INC. | $33,874.80 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $29,934.58 | 2021 | |
| Biogen, INC. | $1,839.02 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $1,363.21 | 2019-2025 | |
| Genzyme Corporation | $1,034.15 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $883.47 | 2022 | |
| Lundbeck LLC | $724.35 | 2020-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $723.59 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $544.82 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $485.98 | 2019-2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $444.18 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Pfizer INC. | $436.06 | 2023-2025 | |
| Ucb, INC. | $422.28 | 2019-2025 | Rystiggo, Zilbrysq |
| Amgen INC. | $362.57 | 2019-2025 | Uplizna |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.